{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:43:20Z","timestamp":1792478600888,"version":"4.5.0"},"reference-count":44,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15868","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:42:22Z","timestamp":1789558942000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Focal adhesion kinase inhibitor defactinib enhances olaparib\u2011induced suppression of BRCA\u2011proficient breast cancer cell proliferation"],"prefix":"10.3892","volume":"32","author":[{"given":"Hisako","family":"Ono","sequence":"first","affiliation":[{"name":"Department of Drug Discovery Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602\u20118566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602\u20118566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602\u20118566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamiko","family":"Sukeno","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602\u20118566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Breast Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602\u20118566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Naoi","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Breast Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602\u20118566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mano","family":"Horinaka","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602\u20118566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602\u20118566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"key20261020093233_b1-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patient with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"key20261020093233_b2-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"key20261020093233_b3-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.2020.38.15_suppl.1002","article-title":"TBCRC 048: Phase II Study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20261020093233_b4-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1038\/s41467-018-06581-8","article-title":"Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls","volume":"9","author":"Momozawa","year":"2018","journal-title":"Nat Commun"},{"key":"key20261020093233_b5-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/annonc\/mdw209","article-title":"Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic","volume":"27","author":"Winter","year":"2016","journal-title":"Ann Oncol"},{"key":"key20261020093233_b6-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"key20261020093233_b7-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"key":"key20261020093233_b8-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov"},{"key":"key20261020093233_b9-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov"},{"key":"key20261020093233_b10-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13058-015-0534-y","article-title":"Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells","volume":"17","author":"Min","year":"2015","journal-title":"Breast Cancer Res"},{"key":"key20261020093233_b11-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10549-018-4815-x","article-title":"The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway","volume":"171","author":"Ono","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"key20261020093233_b12-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1111\/cas.15071","article-title":"Novel RAF\/MEK inhibitor CH5126766\/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer","volume":"112","author":"Ono","year":"2021","journal-title":"Cancer Sci"},{"key":"key20261020093233_b13-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"11922","DOI":"10.1038\/s41598-023-39093-7","article-title":"Identification of c-Met as a novel target of \u03b3-glutamylcyclotransferase","volume":"24","author":"Saito","year":"2023","journal-title":"Sci Rep"},{"key":"key20261020093233_b14-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1158\/1535-7163.MCT-20-0848","article-title":"PARP and CDK4\/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer","volume":"20","author":"Wu","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"key20261020093233_b15-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"8487","DOI":"10.1073\/pnas.89.18.8487","article-title":"Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin","volume":"89","author":"Hanks","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20261020093233_b16-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1073\/pnas.89.11.5192","article-title":"pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions","volume":"89","author":"Schaller","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20261020093233_b17-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ceb.2006.08.011","article-title":"Integrin-regulated FAK-Src signaling in normal and cancer cells","volume":"18","author":"Mitra","year":"2006","journal-title":"Curr Opin Cell Biol"},{"key":"key20261020093233_b18-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/15216540211470","article-title":"The focal adhesion kinase-a regulator of cell migration and invasion","volume":"53","author":"Hauck","year":"2002","journal-title":"IUBMB Life"},{"key":"key20261020093233_b19-ol-32-5-15868","first-page":"252","article-title":"Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling","volume":"119","author":"Pylayeva","year":"2009","journal-title":"J Clin Invest"},{"key":"key20261020093233_b20-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3390\/cancers11111683","article-title":"Role of focal adhesion kinase in small-cell lung cancer and its potential as a therapeutic target","volume":"29","author":"Aboubakar Nana","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20261020093233_b21-ol-32-5-15868","first-page":"624992","article-title":"FAK inhibition suppresses breast cancer progression via DNA methylation-mediated DAB2 gene reactivation","volume":"10","author":"Murphy","year":"2024","journal-title":"BioRxiv"},{"key":"key20261020093233_b22-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1158\/0008-5472.CAN-12-3937","article-title":"Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity","volume":"1","author":"Ishii","year":"2013","journal-title":"Cancer Res"},{"key":"key20261020093233_b23-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"108234","DOI":"10.1016\/j.pharmthera.2022.108234","article-title":"\u2018RB-reactivator screening\u2019 as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist)","volume":"236","author":"Sakai","year":"2022","journal-title":"Pharmacol Ther"},{"key":"key20261020093233_b24-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ygyno.2024.01.028","article-title":"Preclinical efficacy of RAF\/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer","volume":"183","author":"McNamara","year":"2024","journal-title":"Gynecol Oncol"},{"key":"key20261020093233_b25-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"101832","DOI":"10.1136\/ijgc-2024-005919","article-title":"GOG-3097\/ENGOT-ov81\/GTG-UK\/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer","volume":"35","author":"Grisham","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"key20261020093233_b26-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.2217\/fon-2021-1582","article-title":"Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: The RAMP-202 phase II trial","volume":"18","author":"Capelletto","year":"2022","journal-title":"Future Oncol"},{"key":"key20261020093233_b27-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41416-024-02727-2","article-title":"Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer","volume":"131","author":"Yoshimura","year":"2024","journal-title":"Br J Cancer"},{"key":"key20261020093233_b28-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"101943","DOI":"10.1016\/j.xcrm.2025.101943","article-title":"Combined inhibition of focal adhesion kinase and RAF\/MEK elicits synergistic inhibition of melanoma growth and reduces metastases","volume":"6","author":"Almazan","year":"2025","journal-title":"Cell Rep Med"},{"key":"key20261020093233_b29-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1158\/1078-0432.CCR-15-2603","article-title":"Focal adhesion kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer","volume":"22","author":"Tang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20261020093233_b30-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12282-012-0356-z","article-title":"Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells","volume":"21","author":"Shimo","year":"2014","journal-title":"Breast Cancer"},{"key":"key20261020093233_b31-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.2147\/OTT.S89154","article-title":"Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2\/M arrest and gamma-H2AX foci formation in colorectal cancer","volume":"8","author":"Xu","year":"2015","journal-title":"Onco Targets Ther"},{"key":"key20261020093233_b32-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.3390\/ijms21072346","article-title":"Understanding MAPK signaling pathways in apoptosis","volume":"21","author":"Yue","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20261020093233_b33-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","article-title":"Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery","volume":"91","author":"Datta","year":"1997","journal-title":"Cell"},{"key":"key20261020093233_b34-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccr.2009.04.012","article-title":"AKT independent signaling downstream of oncogenic PIK3CA mutations in human cancer","volume":"16","author":"Vasudevan","year":"2009","journal-title":"Cancer Cell"},{"key":"key20261020093233_b35-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/sj.bjc.6602928","article-title":"COSMIC 2005","volume":"94","author":"Forbes","year":"2006","journal-title":"Br J Cancer"},{"key":"key20261020093233_b36-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"CAPItello-291 study group, Capivasertib in hormone receptor-positive advanced breast cancer","volume":"38","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"key20261020093233_b37-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"20693","DOI":"10.1074\/jbc.274.29.20693","article-title":"PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase\/Akt cell survival pathway","volume":"274","author":"Tamura","year":"1999","journal-title":"J Biol Chem"},{"key":"key20261020093233_b38-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"key20261020093233_b39-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"PAOLA-1 Investigators, Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"key20261020093233_b40-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"PRIMA\/ENGOT-OV26\/GOG-3012 Investigators, Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"key20261020093233_b41-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"key20261020093233_b42-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/cas.16033","article-title":"BRCA1\/2 reversion mutations in a pan-cancer cohort","volume":"115","author":"Nakamura","year":"2024","journal-title":"Cancer Sci"},{"key":"key20261020093233_b43-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41416-023-02567-6","article-title":"Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer","volume":"130","author":"Nicum","year":"2024","journal-title":"Br J Cancer"},{"key":"key20261020093233_b44-ol-32-5-15868","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.2217\/fon-2022-0666","article-title":"EPIK-O\/ENGOT-OV61: Alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)","volume":"18","author":"Konstantinopoulos","year":"2022","journal-title":"Future Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:32:39Z","timestamp":1792477959000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15868","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}